A Study of ELND002 in Patients With Relapsing Forms of Multiple Sclerosis

An Open-Label, Long-Term, Follow-Up Study of Subcutaneous ELND002 in Patients With Relapsing Forms of Multiple Sclerosis

Status

Terminated

Phases

Phase 1

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01318421

Enrollment

Registered

2011-03-18

Start date

2010-12-31

Completion date

Unknown

Last updated

2015-12-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Multiple Sclerosis

Keywords

Relapsing forms of secondary progressive multiple sclerosis (SPMS)or relapsing-remitting multiple sclerosis (RRMS)

Brief summary

The purpose of this study is to evaluate the long-term safety and tolerability of ELND002 in patients with multiple sclerosis (MS) after participation in study MS103.

Interventions

DRUGELND002

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 65 Years

Healthy volunteers

Inclusion criteria

* This study is open only to subjects who have completed the week 12 visit in study ELND002-MS103 while taking their assigned dose of study drug.

Exclusion criteria

* Subject has no new medical contraindications to continue participation in the study.

Design outcomes

Primary

Measure	Time frame	Description
To determine the safety and tolerability of ELND002 including the identification of dose-limiting toxicity(ies) (DLT).	1 year	Safety and tolerability will be assessed by frequency and severity of AEs.

Secondary

Measure	Time frame	Description
To evaluate the PK/PD/BM measurement of ELND002 in patients with MS.	1 year	Measurement of drug concentration, alpha 4 receptor saturation, soluble VCAM and MADCAM.

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026